Benevich Eric insider trades
Benevich Eric has filed 30 Form 4s with the SEC that we hold, for Neurocrine Biosciences INC (NBIX) (Chief Commercial Officer) and aTYR PHARMA INC (ATYR) (Director). Across all of them we count 0 purchases worth $0 and 36 sales worth $40.0M reported on Form 4. In the last 12 months: 0 purchases ($0) and 2 sales ($1.2M). The largest single trade was a sale of 69,521 shares of Neurocrine Biosciences INC worth $9.7M, dated 2024-03-14. Of 1 sale filed since we began reading the 10b5-1 checkbox, 1 (100%) was marked as made under a 10b5-1 trading plan. The first filing on our record is dated 2021-08-18 and the latest 2026-09-15.
Neurocrine Biosciences INC (NBIX)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2021-08-16 | S, sale reported on Form 4 | 5,628 | $504.4K | 2021-08-18 |
| 2022-02-07 | S, sale reported on Form 4 | 2,030 | $164.1K | 2022-02-09 |
| 2022-02-07 | S, sale reported on Form 4 | 809 | $65.3K | 2022-02-09 |
| 2022-02-07 | S, sale reported on Form 4 | 1,280 | $103.4K | 2022-02-09 |
| 2022-02-08 | S, sale reported on Form 4 | 980 | $78.1K | 2022-02-09 |
| 2022-10-17 | S, sale reported on Form 4 | 4,960 | $549.7K | 2022-10-19 |
| 2022-11-02 | S, sale reported on Form 4 | 400 | $50.0K | 2022-11-04 |
| 2022-11-03 | S, sale reported on Form 4 | 8,968 | $1.1M | 2022-11-04 |
| 2022-11-08 | S, sale reported on Form 4 | 24,593 | $3.1M | 2022-11-10 |
| 2022-11-10 | S, sale reported on Form 4 | 100 | $12.5K | 2022-11-10 |
| 2022-11-30 | S, sale reported on Form 4 | 22,162 | $2.8M | 2022-12-01 |
| 2022-11-30 | S, sale reported on Form 4 | 20,063 | $2.5M | 2022-12-01 |
| 2022-11-30 | S, sale reported on Form 4 | 7,775 | $978.9K | 2022-12-01 |
| 2023-01-06 | S, sale reported on Form 4 | 400 | $50.0K | 2023-01-10 |
| 2023-01-31 | S, sale reported on Form 4 | 1,207 | $132.7K | 2023-02-02 |
| 2023-02-06 | S, sale reported on Form 4 | 1,280 | $135.2K | 2023-02-08 |
| 2023-02-07 | S, sale reported on Form 4 | 2,030 | $207.6K | 2023-02-08 |
| 2023-02-07 | S, sale reported on Form 4 | 15,360 | $1.6M | 2023-02-08 |
| 2023-02-08 | S, sale reported on Form 4 | 980 | $102.0K | 2023-02-08 |
| 2023-08-21 | S, sale reported on Form 4 | 1,600 | $171.8K | 2023-08-23 |
| 2024-01-31 | S, sale reported on Form 4 | 1,207 | $169.9K | 2024-02-02 |
| 2024-02-06 | S, sale reported on Form 4 | 1,280 | $181.9K | 2024-02-08 |
| 2024-02-08 | S, sale reported on Form 4 | 980 | $131.5K | 2024-02-08 |
| 2024-02-13 | S, sale reported on Form 4 | 1,098 | $146.0K | 2024-02-15 |
| 2024-02-28 | S, sale reported on Form 4 | 53,143 | $7.2M | 2024-02-29 |
| 2024-02-28 | S, sale reported on Form 4 | 21,857 | $2.9M | 2024-02-29 |
| 2024-03-14 | S, sale reported on Form 4 | 5,479 | $763.7K | 2024-03-15 |
| 2024-03-14 | S, sale reported on Form 4 | 69,521 | $9.7M | 2024-03-15 |
| 2024-04-15 | S, sale reported on Form 4 | 7,231 | $964.3K | 2024-04-17 |
| 2024-04-15 | S, sale reported on Form 4 | 12,587 | $1.7M | 2024-04-17 |
| 2025-01-31 | S, sale reported on Form 4 | 1,207 | $184.6K | 2025-02-04 |
| 2025-02-10 | S, sale reported on Form 4 | 980 | $115.9K | 2025-02-12 |
| 2025-02-13 | S, sale reported on Form 4 | 1,056 | $123.2K | 2025-02-14 |
| 2025-02-13 | S, sale reported on Form 4 | 1,098 | $128.2K | 2025-02-14 |
| 2025-11-28 | S, sale reported on Form 4 | 5,970 | $905.9K | 2025-12-02 |
| 2026-09-09 | S, sale reported on Form 4 | 2,154 | $333.0K | 2026-09-10 |
aTYR PHARMA INC (ATYR)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Counted from the Form 4 filings this reporting owner (SEC CIK 1643653) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms